NC
PTCT icon

nVerses Capital’s PTC Therapeutics PTCT Stock Holding History

nVerses Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
+4,494
New +$325K 0.56% 25
2024
Q2 		– Sell
-2,000
Closed -$58.2K – 1165
2024
Q1 		$58.2K Buy
+2,000
New +$56K 0.14% 256

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

nVerses Capital's PTCT Position: Q2 2026 in Review

nVerses Capital opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 4,494 shares worth $367K. The stake represents 0.56% of the portfolio and ranks #25 among its holdings. This is a return to the name: nVerses Capital previously reported a position in PTCT as recently as Q1 2024.

nVerses Capital first reported a position in PTCT in Q1 2024 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • nVerses Capital held 4,494 shares of PTC Therapeutics worth $367K as of Q2 2026.
  • PTC Therapeutics was a new nVerses Capital position in Q2 2026.
  • PTC Therapeutics made up 0.56% of nVerses Capital's portfolio in Q2 2026, its #25 holding.
  • nVerses Capital first reported a position in PTC Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.